Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Very Bullish +85

Why Robotic Surgery's Titan, Intuitive Surgical, Just Made A Bullish Move - Investor's Business Daily

📈 Intuitive Surgical (ISRG) stock jumped 7.2% to close at $483.62 after beating first-quarter earnings expectations and raising its full-year outlook.

💰 Sales grew 23% year-over-year to $2.77 billion, significantly surpassing the Street's estimate of $2.62 billion.

📊 Adjusted earnings per share came in at $2.50, well above the consensus expectation of $2.12, representing a 38% increase from last year.

🔧 Procedures performed using the da Vinci and Ion robotic systems are projected to grow by 13.5% to 15.5% this year, revised up from prior guidance.

💉 Actual procedure growth in the first quarter reached 17%, exceeding analyst forecasts of 14.5%.

🤖 Utilization of the new da Vinci 5 system in the U.S. increased by 11% compared to its predecessor, now supporting emergency procedures like appendectomies.

🌍 International demand remains strong despite budget constraints and competition, particularly in Europe where the da Vinci 5 launch is expanding.

🔥 The Ion robotic system saw impressive 39% growth in procedures, specifically for lung biopsies.

📦 Intuitive Surgical placed 431 new da Vinci systems globally during the quarter, with a total installed base of over 11,000 units now active.

🛒 Revenue from new system placements rose approximately 24.5% to $651 million, while sales of instruments and accessories jumped 23% to $1.69 billion.

⚠️ Analysts noted minor headwinds including weakness in the Asian market, slightly lower-than-expected U.S. placements, and a slowdown in bariatric surgeries linked to weight-loss drug popularity.

👍 Both Leerink Partners and William Blair analysts maintain an "outperform" rating on the stock despite these minor challenges.

🎯 Leerink analyst Mike Kratky cut his price target from $622 to $573 to reflect broader sector valuation compression but remains bullish on the long-term outlook.

Bullish Signals
  • Intuitive Surgical beat first-quarter forecasts with sales growing 23% to $2.77 billion, surpassing analyst expectations of $2.62 billion.
  • Adjusted earnings per share reached $2.50, handily topping the Street's expectation of $2.12, representing a 38% increase in earnings.
  • The company raised its full-year outlook for procedure volume to between 13.5% and 15.5% growth, improving its prior guidance.
  • Procedures grew 17% in Q1, significantly exceeding the expectation of 14.5%, which drives demand for single-use tools and accessories.
  • The new da Vinci 5 system achieved 11% higher utilization than its predecessor, with strong international demand particularly in Europe.
  • Ion robotic surgery systems saw a robust 39% growth in procedures, indicating strong adoption for lung biopsies.
  • Intuitive Surgical placed 431 da Vinci systems, marking a 17% increase over the prior year period.
  • Revenue from system placements rose 24.5% to $651 million, while sales of instruments and accessories jumped 23% to $1.69 billion.
  • Stock jumped 7.2% on Wednesday, closing above its 50-day moving average for the first time since January.
Risk Factors
  • The company faces pockets of weakness in the Asia region.
  • U.S. system placements were slightly lower than expected.
  • There is a 10% slowdown in bariatric procedures globally.
  • International stocking orders experienced a 10% slowdown which could cloud the recent sales beat.
  • Leerink analyst Mike Kratky cut his price target from $622 to $573 due to compression in large-cap medtech sector valuations.
  • Analyst William Blair noted that the bariatric slowdown is potentially related to strong demand for weight-loss drugs, which could divert focus from surgical procedures.
Full Analysis
Intuitive Surgical (ISRG) stock surged 7.2% on Wednesday to close at $483.62 after the company reported stronger-than-expected first-quarter results and raised its full-year procedural outlook. The medical technology giant beat estimates with quarterly sales growing 23% year-over-year to $2.77 billion, compared to analyst expectations of $2.62 billion, and adjusted earnings per share of $2.50 against a forecast of $2.12. Consequently, the stock retested its 50-day moving average for the first time since January, signaling renewed investor confidence following a dip on Tuesday. For the current fiscal year, Intuitive Surgical now expects procedure volumes using its da Vinci and Ion robotic systems to increase between 13.5% and 15.5%, an upward revision of 0.5% from prior guidance that aligns with FactSet analyst forecasts of roughly 14.3%. The first quarter saw procedures climb 17% versus the 14.5% Wall Street forecast, driven by a 23% year-over-year jump in sales of instruments and accessories to $1.69 billion. This growth was powered by the newer da Vinci 5 system, which achieved 11% higher utilization than its predecessor, da Vinci Xi, and gained approval for emergency procedures such as appendectomies. Key drivers for the recent outperformance included a 17% increase in total da Vinci systems placed (totaling 431 units) and a significant 58% rise in placements of the newest iteration, alongside strong demand for its Ion lung biopsy system which saw procedure volumes jump 39%. However, analysts noted certain headwinds, including a 10% slowdown in bariatric procedures—potentially influenced by high demand for weight-loss drugs—and lower-than-expected system placements in the U.S. and pockets of weakness in Asia, according to reports from William Blair and Leerink Partners. Despite these challenges, major analysts like Mike Kratky of Leerink and Brandon Vasquez of William Blair maintained their "outperform" ratings on the stock, acknowledging that tailwinds continue to outweigh recent market concerns.